This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Price, L. B.
Right arrow Articles by Keim, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Price, L. B.
Right arrow Articles by Keim, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2003, p. 2362-2365, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2362-2365.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Selection and Characterization of Bacillus anthracis Mutants with High-Level Resistance to Ciprofloxacin

Lance B. Price,1,2 Amy Vogler,1 Talima Pearson,1 Joseph D. Busch,1 James M. Schupp,1 and Paul Keim1*

Department of Biological Sciences, Northern Arizona University, Flagstaff, Arizona 86011-5640,1 Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 212052

Received 13 August 2002/ Returned for modification 28 October 2002/ Accepted 26 March 2003

Mutants of attenuated Bacillus anthracis with high-level ciprofloxacin resistance were isolated using a three-step in vitro selection. Ciprofloxacin MICs were 0.5 µg/ml for first-step mutants, which had one of two gyrA quinolone resistance-determining region (QRDR) mutations. Ciprofloxacin MICs were 8 and 16 µg/ml for second-step mutants, which had one of three parC QRDR mutations. Ciprofloxacin MICs for third-step mutants were 32 and 64 µg/ml. Mutants for which MICs were 64 µg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR. Mutants for which MICs were 32 µg/ml had no additional target modifications but showed evidence of enhanced ciprofloxacin efflux.

* Corresponding author. Mailing address: Department of Biological Sciences, Northern Arizona University, Flagstaff, AZ 86011-5640. Phone: (928) 523-1078. Fax: (928) 523-0639. E-mail: Paul.Keim{at}nau.edu.

Antimicrobial Agents and Chemotherapy, July 2003, p. 2362-2365, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2362-2365.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Heine, H. S., Bassett, J., Miller, L., Bassett, A., Ivins, B. E., Lehoux, D., Arhin, F. F., Parr, T. R. Jr., Moeck, G. (2008). Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax. Antimicrob. Agents Chemother. 52: 3350-3357 [Abstract] [Full Text]  
  • Heine, H. S., Bassett, J., Miller, L., Hartings, J. M., Ivins, B. E., Pitt, M. L., Fritz, D., Norris, S. L., Byrne, W. R. (2007). Determination of Antibiotic Efficacy against Bacillus anthracis in a Mouse Aerosol Challenge Model. Antimicrob. Agents Chemother. 51: 1373-1379 [Abstract] [Full Text]  
  • Brook, I., Germana, A., Giraldo, D. E., Camp-Hyde, T. D., Bolduc, D. L., Foriska, M. A., Elliott, T. B., Thakar, J. H., Shoemaker, M. O., Jackson, W. E., Ledney, G. D. (2005). Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice. J Antimicrob Chemother 56: 1074-1080 [Abstract] [Full Text]  
  • Poole, K. (2005). Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56: 20-51 [Abstract] [Full Text]  
  • Korzheva, N., Davies, T. A., Goldschmidt, R. (2005). Novel Ser79Leu and Ser81Ile Substitutions in the Quinolone Resistance-Determining Regions of ParC Topoisomerase IV and GyrA DNA Gyrase Subunits from Recent Fluoroquinolone-Resistant Streptococcus pneumoniae Clinical Isolates. Antimicrob. Agents Chemother. 49: 2479-2486 [Abstract] [Full Text]  
  • Grohs, P., Podglajen, I., Gutmann, L. (2004). Activities of Different Fluoroquinolones against Bacillus anthracis Mutants Selected In Vitro and Harboring Topoisomerase Mutations. Antimicrob. Agents Chemother. 48: 3024-3027 [Abstract] [Full Text]  
  • Athamna, A., Athamna, M., Abu-Rashed, N., Medlej, B., Bast, D. J., Rubinstein, E. (2004). Selection of Bacillus anthracis isolates resistant to antibiotics. J Antimicrob Chemother 54: 424-428 [Abstract] [Full Text]  
  • Bast, D. J., Athamna, A., Duncan, C. L., de Azavedo, J. C. S., Low, D. E., Rahav, G., Farrell, D., Rubinstein, E. (2004). Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance. J Antimicrob Chemother 54: 90-94 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»